Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

The cognitive effects of anxiety and depression in immune-mediated inflammatory diseases.

Feinstein A, Brochet B, Sumowski J.

Neurology. 2019 Jan 11. pii: 10.1212/WNL.0000000000006840. doi: 10.1212/WNL.0000000000006840. [Epub ahead of print] No abstract available.

PMID:
30635489
2.

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.

Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud DA, De Sèze J, Cotton F, Moreau T, Stankoff B, Fontaine B, Guillemin F, Debouverie M, Clanet M.

Mult Scler. 2018 Dec 13:1352458518815602. doi: 10.1177/1352458518815602. [Epub ahead of print]

PMID:
30541380
3.

Longitudinal study of functional brain network reorganization in clinically isolated syndrome.

Koubiyr I, Deloire M, Besson P, Coupé P, Dulau C, Pelletier J, Tourdias T, Audoin B, Brochet B, Ranjeva JP, Ruet A.

Mult Scler. 2018 Nov 27:1352458518813108. doi: 10.1177/1352458518813108. [Epub ahead of print]

PMID:
30480467
4.

Differential Gray Matter Vulnerability in the 1 Year Following a Clinically Isolated Syndrome.

Koubiyr I, Deloire M, Coupé P, Dulau C, Besson P, Moroso A, Planche V, Tourdias T, Brochet B, Ruet A.

Front Neurol. 2018 Oct 11;9:824. doi: 10.3389/fneur.2018.00824. eCollection 2018.

5.

Efficacy of rituximab in refractory RRMS.

Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, Carra-Dalliere C, Labauge P, Mathey G, Debouverie M, Papeix C, Maillart E, Lubetzki C, Bensa C, Gout O, Giannesini C, Stankoff B, Ciron J, Brassat D, Pelletier J, Rico Lamy A, Audoin B; SFSEP and OFSEP groups.

Mult Scler. 2018 May 1:1352458518772748. doi: 10.1177/1352458518772748. [Epub ahead of print]

PMID:
29722639
6.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
7.

Cognitive assessment in patients with multiple sclerosis: From neuropsychological batteries to ecological tools.

Ruet A, Brochet B.

Ann Phys Rehabil Med. 2018 Feb 17. pii: S1877-0657(18)30012-5. doi: 10.1016/j.rehab.2018.01.006. [Epub ahead of print]

PMID:
29462665
8.

Preliminary evidence of the cerebellar role on cognitive performances in clinically isolated syndrome.

Moroso A, Ruet A, Lamargue-Hamel D, Munsch F, Deloire M, Ouallet JC, Cubizolle S, Charré-Morin J, Saubusse A, Tourdias T, Dousset V, Brochet B.

J Neurol Sci. 2018 Feb 15;385:1-6. doi: 10.1016/j.jns.2017.11.037. Epub 2017 Dec 2.

PMID:
29406885
9.

Regional hippocampal vulnerability in early multiple sclerosis: Dynamic pathological spreading from dentate gyrus to CA1.

Planche V, Koubiyr I, Romero JE, Manjon JV, Coupé P, Deloire M, Dousset V, Brochet B, Ruet A, Tourdias T.

Hum Brain Mapp. 2018 Apr;39(4):1814-1824. doi: 10.1002/hbm.23970. Epub 2018 Jan 13.

PMID:
29331060
10.

[Towards a national strategy on the diagnosis of neurocognitive disorders. A shared approach among the French National College of General Practitioners and specialists of neurocognitive disorders].

Krolak-Salmon P, Letrilliart L, Ceccaldi M, Andrieu S, Guérin O, Dubois B, Brochet B, Vandel P, Jeandel C, Leperre-Desplanques A, Clanet M, Druais PL.

Presse Med. 2018 Jan;47(1):75-83. doi: 10.1016/j.lpm.2017.10.029. Epub 2017 Dec 26. French.

PMID:
29287728
11.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
12.

Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year.

Cohen M, Brochet B, Clavelou P, Le Page E, Vermersch P, Tourbah A, Moreau T, Joly H, Sakarovitch C, Lebrun C; Qualicis Study Group.

J Neurol Sci. 2017 Nov 15;382:73-78. doi: 10.1016/j.jns.2017.09.030. Epub 2017 Sep 22.

PMID:
29111024
13.

Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.

Planche V, Moisset X, Morello R, Dumont E, Gibelin M, Charré-Morin J, Saubusse A, Mondou A, Reuter F, Defer G, Pelletier J, Brochet B, Clavelou P.

J Neurol Sci. 2017 Nov 15;382:148-154. doi: 10.1016/j.jns.2017.10.008. Epub 2017 Oct 6.

PMID:
29111011
14.

Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France.

Biotti D, Bonneville F, Tournaire E, Ayrignac X, Dallière CC, Mahieu L, Vignal C, Dulau C, Brochet B, Ruet A, Ouallet JC, Gout O, Heran F, Menjot de Champfleur N, Tourdias T, Deneve M, Labauge P, Deschamps R.

J Neurol. 2017 Oct;264(10):2173-2175. doi: 10.1007/s00415-017-8615-8. Epub 2017 Sep 15. No abstract available.

PMID:
28914353
15.

Pattern separation performance is decreased in patients with early multiple sclerosis.

Planche V, Ruet A, Charré-Morin J, Deloire M, Brochet B, Tourdias T.

Brain Behav. 2017 Jun 21;7(8):e00739. doi: 10.1002/brb3.739. eCollection 2017 Aug.

16.

Microstructural analyses of the posterior cerebellar lobules in relapsing-onset multiple sclerosis and their implication in cognitive impairment.

Moroso A, Ruet A, Lamargue-Hamel D, Munsch F, Deloire M, Coupé P, Charré-Morin J, Saubusse A, Ouallet JC, Planche V, Tourdias T, Dousset V, Brochet B.

PLoS One. 2017 Aug 8;12(8):e0182479. doi: 10.1371/journal.pone.0182479. eCollection 2017.

17.

Functional training is a senseless strategy in MS cognitive rehabilitation: Strategy training is the only useful approach - Commentary.

Brochet B.

Mult Scler. 2017 Jun;23(7):932-933. doi: 10.1177/1352458517699877. Epub 2017 Mar 23. No abstract available.

PMID:
28332941
18.

Social cognition according to cognitive impairment in different clinical phenotypes of multiple sclerosis.

Dulau C, Deloire M, Diaz H, Saubusse A, Charre-Morin J, Prouteau A, Brochet B.

J Neurol. 2017 Apr;264(4):740-748. doi: 10.1007/s00415-017-8417-z. Epub 2017 Feb 20.

PMID:
28220288
19.

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.

Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Sèze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A; PROMESS study investigators.

PLoS One. 2017 Jan 3;12(1):e0168834. doi: 10.1371/journal.pone.0168834. eCollection 2017.

20.

Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP).

Mult Scler. 2017 Sep;23(10):1377-1384. doi: 10.1177/1352458516678474. Epub 2016 Nov 25.

PMID:
27885065
21.

Selective dentate gyrus disruption causes memory impairment at the early stage of experimental multiple sclerosis.

Planche V, Panatier A, Hiba B, Ducourneau EG, Raffard G, Dubourdieu N, Maitre M, Lesté-Lasserre T, Brochet B, Dousset V, Desmedt A, Oliet SH, Tourdias T.

Brain Behav Immun. 2017 Feb;60:240-254. doi: 10.1016/j.bbi.2016.11.010. Epub 2016 Nov 12.

PMID:
27847283
22.

Cerebellar Assessment in Early Multiple Sclerosis.

Moroso A, Ruet A, Deloire M, Lamargue-Hamel D, Cubizolle S, Charré-Morin J, Saubusse A, Brochet B.

Cerebellum. 2017 Apr;16(2):607-611. doi: 10.1007/s12311-016-0831-8.

PMID:
27815857
23.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
24.

Posterior lobules of the cerebellum and information processing speed at various stages of multiple sclerosis.

Moroso A, Ruet A, Lamargue-Hamel D, Munsch F, Deloire M, Coupé P, Ouallet JC, Planche V, Moscufo N, Meier DS, Tourdias T, Guttmann CR, Dousset V, Brochet B.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):146-151. doi: 10.1136/jnnp-2016-313867. Epub 2016 Oct 27.

25.

Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis.

Planche V, Ruet A, Coupé P, Lamargue-Hamel D, Deloire M, Pereira B, Manjon JV, Munsch F, Moscufo N, Meier DS, Guttmann CR, Dousset V, Brochet B, Tourdias T.

Mult Scler. 2017 Aug;23(9):1214-1224. doi: 10.1177/1352458516675750. Epub 2016 Oct 25.

PMID:
27780913
26.

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.

Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.

27.

Who Performs Lumbar Puncture, How Many Do They Perform, How and Why? A Retrospective Study of 6,594 Cases.

Moisset X, Ruet A, Brochet B, Planche V, Jaffeux P, Gilleron V, Ong N, Clavelou P.

Eur Neurol. 2016;76(1-2):8-11. doi: 10.1159/000447452. Epub 2016 Jun 24.

PMID:
27336667
28.

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.

Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G.

J Neurol Sci. 2016 Apr 15;363:69-76. doi: 10.1016/j.jns.2016.02.012. Epub 2016 Feb 6.

PMID:
27000224
29.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

30.

EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients.

Durand T, Jacob S, Lebouil L, Douzane H, Lestaevel P, Rahimian A, Psimaras D, Feuvret L, Leclercq D, Brochet B, Tamarat R, Milliat F, Benderitter M, Vayatis N, Noël G, Hoang-Xuan K, Delattre JY, Ricard D, Bernier MO.

BMC Neurol. 2015 Dec 18;15:261. doi: 10.1186/s12883-015-0519-6.

31.

Cognitive evaluation by tasks in a virtual reality environment in multiple sclerosis.

Lamargue-Hamel D, Deloire M, Saubusse A, Ruet A, Taillard J, Philip P, Brochet B.

J Neurol Sci. 2015 Dec 15;359(1-2):94-9. doi: 10.1016/j.jns.2015.10.039. Epub 2015 Oct 23.

PMID:
26671094
32.

Deciphering Depressive Mood in Relapsing-Remitting and Progressive Multiple Sclerosis and Its Consequence on Quality of Life.

Lamargue Hamel D, Deloire M, Ruet A, Charré-Morin J, Saubusse A, Ouallet JC, Brochet B.

PLoS One. 2015 Nov 10;10(11):e0142152. doi: 10.1371/journal.pone.0142152. eCollection 2015.

33.

Efficacy of rituximab in refractory neuromyelitis optica.

Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R; OFSEP and CFSEP.

Mult Scler. 2016 Jun;22(7):955-9. doi: 10.1177/1352458515602337. Epub 2015 Sep 11.

PMID:
26362900
34.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis.

Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11.

PMID:
26362898
35.

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G.

PLoS One. 2015 Jul 6;10(7):e0132033. doi: 10.1371/journal.pone.0132033. eCollection 2015.

36.

Does cerebrospinal fluid analysis add predictive value to magnetic resonance imaging for long term irreversible disability in patients with early multiple sclerosis?

Moroso A, Deloire MS, Ruet A, Ouallet JC, Casey R, Brochet B.

J Neurol Sci. 2015 Jul 15;354(1-2):51-5. doi: 10.1016/j.jns.2015.04.044. Epub 2015 May 2.

PMID:
25977107
37.

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P.

J Neurol. 2015 Jul;262(7):1637-45. doi: 10.1007/s00415-015-7758-8. Epub 2015 May 1.

PMID:
25929666
38.

Presumed tuberculous retrobulbar optic neuritis: a diagnosis challenge.

Aupy J, Vital A, Rougier MB, Gradel A, Meissner W, Marchal C, Penchet G, Brochet B.

J Neurol. 2015 Feb;262(2):481-4. doi: 10.1007/s00415-014-7611-5. Epub 2014 Dec 24. No abstract available.

PMID:
25536904
39.

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P.

Brain. 2015 Feb;138(Pt 2):284-92. doi: 10.1093/brain/awu353. Epub 2014 Dec 19.

PMID:
25527826
40.

Information processing speed impairment and cerebellar dysfunction in relapsing-remitting multiple sclerosis.

Ruet A, Hamel D, Deloire MS, Charré-Morin J, Saubusse A, Brochet B.

J Neurol Sci. 2014 Dec 15;347(1-2):246-50. doi: 10.1016/j.jns.2014.10.008. Epub 2014 Oct 12.

PMID:
25454642
41.

MS lesions are better detected with 3D T1 gradient-echo than with 2D T1 spin-echo gadolinium-enhanced imaging at 3T.

Crombé A, Saranathan M, Ruet A, Durieux M, de Roquefeuil E, Ouallet JC, Brochet B, Dousset V, Tourdias T.

AJNR Am J Neuroradiol. 2015 Mar;36(3):501-7. doi: 10.3174/ajnr.A4152. Epub 2014 Nov 6.

42.

Early predictors of multiple sclerosis after a typical clinically isolated syndrome.

Ruet A, Arrambide G, Brochet B, Auger C, Simon E, Rovira A, Montalban X, Tintoré M.

Mult Scler. 2014 Nov;20(13):1721-6. doi: 10.1177/1352458514533397. Epub 2014 May 19.

PMID:
24842960
43.

Radiologically isolated syndrome: 5-year risk for an initial clinical event.

Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, Keegan BM, Donlon S, Hua le H, Vidal-Jordana A, Montalban X, Rovira A, Tintoré M, Amato MP, Brochet B, de Seze J, Brassat D, Vermersch P, De Stefano N, Sormani MP, Pelletier D, Lebrun C; Radiologically Isolated Syndrome Consortium (RISC); Club Francophone de la Sclérose en Plaques (CFSEP).

PLoS One. 2014 Mar 5;9(3):e90509. doi: 10.1371/journal.pone.0090509. eCollection 2014.

44.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators.

JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.

PMID:
24566807
45.

[Cavitary lesions in multiple sclerosis: multicenter study on twenty patients].

Corlobé A, Renard D, Goizet C, Berger E, Rumbach L, Robinson A, Dupuy D, Touzé E, Zéphir H, Vermersch P, Brochet B, Edan G, Deburghgraeve V, Créange A, Castelnovo G, Cohen M, Lebrun-Frenay C, Boespflug-Tanguy O, Labauge P.

Rev Neurol (Paris). 2013 Dec;169(12):965-9. doi: 10.1016/j.neurol.2013.02.010. Epub 2013 Oct 17. French.

PMID:
24139243
46.

[Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? Yes].

Brochet B.

Rev Neurol (Paris). 2013 Nov;169(11):858-63. doi: 10.1016/j.neurol.2013.08.003. Epub 2013 Oct 2. French.

PMID:
24094530
47.

Probable medications overuse headaches: validation of a brief easy-to-use screening tool in a headache centre.

Dousset V, Maud M, Legoff M, Radat F, Brochet B, Dartigues JF, Kurth T.

J Headache Pain. 2013 Oct 2;14:81. doi: 10.1186/1129-2377-14-81.

48.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

49.

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H.

Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7.

PMID:
23925765
50.

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D; BIONAT Network,; CFSEP.

Eur J Neurol. 2014;21(1):40-8. doi: 10.1111/ene.12204. Epub 2013 Jun 12.

PMID:
23895407

Supplemental Content

Loading ...
Support Center